NO20024159L - Derivatives of quinoline as alpha-2 antagonists - Google Patents

Derivatives of quinoline as alpha-2 antagonists

Info

Publication number
NO20024159L
NO20024159L NO20024159A NO20024159A NO20024159L NO 20024159 L NO20024159 L NO 20024159L NO 20024159 A NO20024159 A NO 20024159A NO 20024159 A NO20024159 A NO 20024159A NO 20024159 L NO20024159 L NO 20024159L
Authority
NO
Norway
Prior art keywords
quinoline
antagonists
alpha
derivatives
Prior art date
Application number
NO20024159A
Other languages
Norwegian (no)
Other versions
NO20024159D0 (en
Inventor
Siegfried Wurster
Mia Enstroem
Juha-Matti Savola
Lisa Hoeglund
Jukka Sallinen
Antti Haapalinna
Andrei Tauber
Anna-Marja Hoffren
Harri Salo
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of NO20024159D0 publication Critical patent/NO20024159D0/en
Publication of NO20024159L publication Critical patent/NO20024159L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20024159A 2000-03-01 2002-08-30 Derivatives of quinoline as alpha-2 antagonists NO20024159L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (en) 2000-03-01 2000-03-01 Quinoline and naphthalene derivatives as alpha-2 antagonists
PCT/FI2001/000203 WO2001064645A2 (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists

Publications (2)

Publication Number Publication Date
NO20024159D0 NO20024159D0 (en) 2002-08-30
NO20024159L true NO20024159L (en) 2002-08-30

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024159A NO20024159L (en) 2000-03-01 2002-08-30 Derivatives of quinoline as alpha-2 antagonists

Country Status (21)

Country Link
EP (1) EP1263733A2 (en)
JP (1) JP2003525274A (en)
KR (1) KR20020089372A (en)
CN (1) CN1468224A (en)
AR (1) AR034249A1 (en)
AU (1) AU2001239331A1 (en)
BR (1) BR0108816A (en)
CA (1) CA2400657A1 (en)
CZ (1) CZ20022880A3 (en)
EE (1) EE200200490A (en)
FI (1) FI20000480A0 (en)
HU (1) HUP0204458A3 (en)
IL (1) IL151093A0 (en)
MX (1) MXPA02008402A (en)
NO (1) NO20024159L (en)
PE (1) PE20011084A1 (en)
PL (1) PL357874A1 (en)
RU (1) RU2002125944A (en)
SK (1) SK12332002A3 (en)
WO (1) WO2001064645A2 (en)
ZA (1) ZA200206956B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1628109A (en) * 2002-02-05 2005-06-15 诺沃挪第克公司 Novel aryl- and heteroarylpiperazines
CA2480266C (en) * 2002-04-03 2011-07-12 Orion Corporation Use of an alpha2-adrenoreceptor antagonist for cns-related diseases
DE60316672T2 (en) 2002-04-03 2008-07-17 Orion Corp. POLYCYCLIC COMPOUNDS AS POTENTIAL ALPHA2 ADRENOCEPTOR ANTAGONISTS
KR100557020B1 (en) * 2002-04-30 2006-03-03 영진약품공업주식회사 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
JP5121707B2 (en) 2005-07-04 2013-01-16 ハイ ポイント ファーマシューティカルズ，エルエルシー New medicine
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
CA2636929A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
EP2029553A1 (en) * 2006-05-22 2009-03-04 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use as a medicine
WO2007135111A1 (en) 2006-05-23 2007-11-29 High Point Pharmaceuticals, Llc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
CA2659570C (en) 2006-05-29 2015-10-06 High Point Pharmaceuticals, Llc 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
TWI457122B (en) 2007-07-20 2014-10-21 Orion Corp 2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
TW201026691A (en) 2008-10-07 2010-07-16 Schering Corp Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
EP2509953B1 (en) * 2009-12-11 2016-03-30 Genecode AS Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
CN103524413B (en) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 hydrogenated acridine derivative and application thereof
JOP20200052A1 (en) * 2013-12-19 2017-06-16 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
WO2015153535A1 (en) * 2014-03-31 2015-10-08 MiRx Pharmaceuticals, LLC Novel hdmx inhibitors and their use for cancer treatment
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (en) * 2017-07-01 2020-04-28 广东医科大学 4-flexible amino-2-arylvinyl quinoline derivative and preparation method and application thereof
CA3230249A1 (en) * 2021-09-07 2023-03-16 Paul Gregor Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
AR034249A1 (en) 2004-02-18
SK12332002A3 (en) 2003-07-01
IL151093A0 (en) 2003-04-10
PL357874A1 (en) 2004-07-26
RU2002125944A (en) 2004-02-27
WO2001064645A3 (en) 2001-12-27
EE200200490A (en) 2003-12-15
MXPA02008402A (en) 2003-10-14
HUP0204458A3 (en) 2004-07-28
CA2400657A1 (en) 2001-09-07
KR20020089372A (en) 2002-11-29
NO20024159D0 (en) 2002-08-30
BR0108816A (en) 2002-12-10
PE20011084A1 (en) 2001-10-25
EP1263733A2 (en) 2002-12-11
AU2001239331A1 (en) 2001-09-12
FI20000480A0 (en) 2000-03-01
CZ20022880A3 (en) 2003-06-18
JP2003525274A (en) 2003-08-26
HUP0204458A2 (en) 2003-04-28
CN1468224A (en) 2004-01-14
WO2001064645A2 (en) 2001-09-07
ZA200206956B (en) 2003-12-01

Similar Documents

Publication Publication Date Title
NO20024159D0 (en) Derivatives of quinoline as alpha-2 antagonists
NO20041235L (en) Quinoline derivatives as neuropeptide Y antagonists
NO20022139D0 (en) Quinazoline derivatives as VEGF inhibitors
NO20024387D0 (en) Carboxylic acid derivatives as IP antagonists
CY2013011I1 (en) METHOD OF ADMINISTRATION OF DIPHOSPHONICS
NO20030055L (en) Colchinol derivatives as angiogenesis inhibitors
DK1406628T3 (en) Tetrahydroquinoline derivatives
DK1650203T3 (en) Quinolinone derivatives as tyrosine kinase inhibitors
NO20015365L (en) Piperidine derivatives useful as CCR5 antagonists
NO20034439L (en) benzamidine derivatives
NO20032142L (en) Substituted 2-phenylaminoimidazoline-phenylketone derivatives as IP antagonists
DK1360184T3 (en) Piperidine derivatives as neurokinin-1 antagonists
NO20021860D0 (en) Formulation of substituted benzimidazoles
DK1464641T3 (en) 4-phenylpiperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists
ATE309994T1 (en) ALKOXYCARBONYLAMINOBENZOIC ACID OR ALKOXYCARBONYLAMINOTETRAZOLYLPHENYL DERIVATIVES AS IP ANTAGONISTS
NO20025542L (en) quinolonecarboxylic acid derivatives
NO20021730L (en) New formulation of mirtazapine
DE60210058D1 (en) ALKOXYCARBONYLAMINO-HETEROARYL CARBOXYLENE DERIVATIVES AS IP ANTAGONISTS
IS6610A (en) New mixtures of alpha-2,4-disulfophenyl-N-tert-butylnitron
NO20023785D0 (en) Water-dispersible formulation of paroxetine
DK1330453T3 (en) Indolylpiperidine derivatives as antihistamine and anti-allergy agents
ATE367379T1 (en) QUINOLINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
NO20021249L (en) Tienoisoxazolphenoxy substituted ethyl and propyl derivatives useful as D4 antagonists
DE50104434D1 (en) LACTAM-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application